DENMARK - Essex-backed Symphogen raise EUR 33m; merges with Receptor BioLogix

Essex Woodland Health Ventures, together with existing investors, has raised EUR 33m for portfolio biopharmaceuticals company Symphogen A/S and simultaneously merged the business with fellow portfolio company, Receptor BioLogix, in an all shares transaction.